The specter of generic competition has long loomed above copyright’s iconic drug, Sildenafil, sparking questions about the prospects of connected drug ventures. While early times saw impressive returns, the patent lapse has allowed the door for discounted copies, potentially reducing earnings and posing a real hazard for stakeholders looking for